Skip to content

A Multi-omics Study of Adenomyosis

A Multi-omics Study on the Tumorigenesis of Adenomyosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03742843
Enrollment
200
Registered
2018-11-15
Start date
2018-11-10
Completion date
2020-11-23
Last updated
2018-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis, Ectopic Endometrium, Endometriosis, Eutopic Endometrium, Genomics, Metabolomics, Transcriptomics

Brief summary

This study aims to analyze the multi-omics results between eutopic endometrium, adenomyosis and endometriosis of patients diagnosed of adenomyosis with and without endometriosis. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the pathogenesis of adenomyosis.

Interventions

COMBINATION_PRODUCTA multi-omics analysis

A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium

Sponsors

Lei Li
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Confirmed adenomyosis and/or endometriosis * Signed an approved informed consents * Feasible for biopsy

Exclusion criteria

* Not meeting all of the inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Frequencies of somatic driving mutationsTwo yearsThe differences of distributions and frequencies of somatic driving mutations will be compared between eutopic endometrium and ectopic endometrium by whole exome sequencing.

Secondary

MeasureTime frameDescription
Frequencies of alteration of RNA expressionTwo yearsThe alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between eutopic endometrium and ectopic endometrium by transcriptome sequencing.
Frequencies of alteration of protein expression and signal pathwayTwo yearsThe alteration of protein expression and signal pathway will be compared between eutopic endometrium and ectopic endometrium by metabolomic sequencing
Progression-free survivalFive yearsProgression-free survival between patients with differential expressed multi-omics will be compared.

Countries

China

Contacts

Primary ContactLei Li, M.D.
lileigh@163.com13911988831

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026